This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Neurocrine Biosciences' CEO Presents At Deutsche Bank 37th Annual Health Care Conference (Transcript)

Neurocrine Biosciences, Inc. (NBIX)

Deutsche Bank 37th Annual Health Care Conference Call

May 09, 2012 11:20 am ET

Executives

Kevin C. Gorman – President and Chief Executive Officer

Analysts

Navdeep Singh – Deutsche Bank Securities, Inc.

Presentation

Navdeep Singh – Deutsche Bank Securities, Inc.

Hey, good morning everyone and thanks for attending the third and final day of the 37th Annual Deutsche Bank Health Care Conference. My name is Navdeep Singh and I’m one of the Deutsche Bank Biotechnology Analyst, and up next we have Neurocrine Biosciences and representing the company is Kevin Gorman, Chief Executive Officer. Kevin?

Kevin C. Gorman

Thank you, Navdeep and thank you to Deutsche Bank for inviting us to the conference. Before I start out, I’ll direct you to our Safe Harbor statement and our resent SEC fillings for an exhaustive detailing of the risk factors because I will be making forward looking statements today.

So I’m going to basically talk about our two main programs at Neurocrine today. The first one being our elagolix program, a small molecule GnRH Antagonists that we partnered with Abbott and Abbott now fully controls and runs this program.

The second program that I’ll be speaking about is our wholly-owned VMAT2 program for movement disorders. And so let’s start right in with the elagolix program. I usually never stop on this slide, but I will today because endometriosis is a condition that is characterized by at times extreme pain.

1 of 4

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,493.37 -69.93 -0.42%
S&P 500 1,925.15 -5.52 -0.29%
NASDAQ 4,352.6390 -17.1340 -0.39%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs